cln-081
Cullinan Oncology
[]
cln-081; phase 1b; egfrex20ins. active, 41% pr rate; mpfs 12m at 100mg bid. ic responses seen. might have a tox advantage as no gd3 rash or diarrhoea seen at proposed dose level. #asco22 . well presented 
Consultant Medical Oncologist, UK. Views are hypothesis generating discourse. Post COVID dabbling in garden.